**To the Editors of The Lancet Digital Health,**

I am pleased to submit our manuscript, entitled *“Cancer Alpha: A Production-Ready, Multi-Modal AI System for Cancer Classification and Interpretation”*, for your consideration. This work presents a fully integrated, clinically aligned artificial intelligence system capable of accurately classifying cancer types across diverse omics profiles — including gene expression, methylation, and histone modification data — using a transformer-based, ensemble learning architecture.

Cancer Alpha is not merely a proof-of-concept. It is production-ready: deployed via FastAPI, containerized with Kubernetes, monitored using Prometheus and Grafana, and designed to integrate into real-world diagnostic workflows. It offers interpretability through feature-level importance scores, empowering clinical insight alongside prediction.

This submission aligns directly with *The Lancet Digital Health*’s mission to feature pioneering work at the intersection of biomedical science, clinical practice, and data-driven technologies. To our knowledge, this is the first system that combines multi-modal omics fusion with a deployment-grade AI stack specifically designed for translational oncology.

A provisional patent has been filed to protect the underlying architecture and application of Cancer Alpha. The manuscript is not under consideration elsewhere.

We believe your readership — particularly those interested in clinical informatics, precision oncology, and AI deployment in healthcare — will find this work timely, rigorous, and impactful.

Thank you for considering our manuscript. We would welcome the opportunity to contribute to your journal.

**Sincerely,**

Dr. R. Craig Stillwell